Especially for immune checkpoints that are less extensively studied in brain tumors, such as IDO1, TIM-3, and CD40, current knowledge is mainly based on research in other malignant brain tumors, such as glioblastoma. This evidence concerns the gene IDO1 and brain neoplasm.